Poly-gamma-glutamic Acid Composition for Non-Surgical CIN Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cervical intraepithelial neoplasia often require surgery, which can lead to severe side effects such as infertility, premature birth, and difficult pregnancy, especially in unmarried or pre-childbirth women, and there is a need for a non-surgical therapeutic method.
Innovation Solution
A composition containing poly-gamma-glutamic acid, aspartame, and a pharmaceutically acceptable excipient is administered to patients with cervical intraepithelial neoplasia, which acts as an immune adjuvant to stimulate the immune system and reduce the molecular weight of poly-gamma-glutamic acid, thereby treating the condition without surgery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical procedures such as cervical conization are performed to treat stage 2 or 3 cervical neoplasia, then the infected site is removed and HPV virus removal is guaranteed, but severe side effects such as infertility, premature birth, and difficult pregnancy occur
Solution Approach 1:
The patent replaces the mechanical surgical intervention (cervical conization) with a chemical/immunological treatment system. The composition containing poly-gamma-glutamic acid, aspartame, and other components acts as an immune adjuvant to stimulate the patient's own immune system to eliminate HPV-infected cells, thereby avoiding mechanical removal of cervical tissue and its associated reproductive side effects.
Solution Approach 2:
The patent introduces a pharmaceutical composition as an intermediary between the HPV infection and the immune response. This composition, particularly through poly-gamma-glutamic acid and aspartame, mediates the immune system's recognition and elimination of infected cells, providing a non-invasive pathway to achieve viral clearance without direct surgical intervention.
2Object-affected harmful factors
If poly-gamma-glutamic acid is used as an immune adjuvant to treat cervical intraepithelial neoplasia, then side effects are avoided and therapeutic effect is achieved, but the molecular weight of poly-gamma-glutamic acid may decrease affecting stability
Solution Approach 1:
The patent creates a composite pharmaceutical composition where poly-gamma-glutamic acid is combined with aspartame and other excipients. This composite formulation not only provides the immune adjuvant effect but also protects poly-gamma-glutamic acid from molecular weight degradation, as aspartame acts as a stabilizing agent that prevents polymer chain breakdown during storage and administration.
Solution Approach 2:
The patent optimizes the molecular weight parameters of poly-gamma-glutamic acid by controlling its degradation rate through combination with aspartame. The composition maintains the molecular weight within a specific range (2,000-3,500 kDa) by using aspartame to inhibit excessive hydrolysis, thereby balancing immunogenicity (which requires adequate molecular weight) with stability (which requires controlled degradation).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively treats cervical intraepithelial neoplasia without causing side effects, maintaining the stability of poly-gamma-glutamic acid's molecular weight and achieving a high therapeutic effect, thus preventing potential infertility and other complications.
Implementation Method 1
A composition containing poly-gamma-glutamic acid, aspartame and a pharmaceutically acceptable excipient is administered to patients with cervical intraepithelial neoplasia, which acts as an immune adjuvant to stimulate the immune system
Data Source
AI summary
The present invention is directed to a method of treating cervical intraepithelial neoplasia by administering a composition containing poly-gamma-glutamic acid. According to the present invention, cervical intraepithelial neoplasia in unmarried women, pre-childbirth women, or women who do not want infertility, can be treated without concern about infertility.